C26-A6，5MG，SML3568-5MG，Sigma

Biochem/physiol Actions

Metadherin-staphylococcal nuclease domain-containing 1 (MTDH-SND1) interaction inhibitor with anti-triple-negative breast cancer (TNBC) efficacy in vivo.
A26-A6 is a MTDH-SND1 interaction blocker (IC50 = 2.4 μM by cell-free & 12.3 μM by cellular split-luc assay) that competes against metadherin (MTDH; AEG-1; LYRIC) for staphylococcal nuclease domain-containing 1 (SND1) binding, thereby preventing MTDH-SND1 complex from suppressing antitumor T cell responses. A26-A6 inhibits PyMT tumor sphere formation in cultures (IC50 <200 μM) in a MTDH- and SND1-dependent manner and exhibits in vivo efficacy against breast tumor growth and metastasis in mice in vivo (15 mg/kg/d i.v. 5d/wk), including the murine PyMT model, and human breast cancer xenografts (PDX, HCI-001, SCP28).